Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangxi Rimag Group Co's ROE % for the quarter that ended in Dec. 2025 was -1.42%. Jiangxi Rimag Group Co's PB Ratio for the quarter that ended in Dec. 2025 was N/A.
Jiangxi Rimag Group Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.
Jiangxi Rimag Group Co ROE % Adjusted to Book Value Related Terms
Jiangxi Rimag Group Co ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Jiangxi Rimag Group Co's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Rimag Group Co ROE % Adjusted to Book Value Chart
FRA:RD9 vs HCA, THC, DVA: ROE % Adjusted to Book Value Comparison
For the Medical Care Facilities subindustry, Jiangxi Rimag Group Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Rimag Group Co ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jiangxi Rimag Group Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Jiangxi Rimag Group Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Jiangxi Rimag Group Co (FRA:RD9) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Jiangxi Rimag Group Co and its competitors.
Is Jiangxi Rimag Group Co's ROE % Adjusted to Book Value too high?
Jiangxi Rimag Group Co's current ROE % Adjusted to Book Value is 0.00%. Overall, Jiangxi Rimag Group Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Rimag Group Co's ROE % Adjusted to Book Value compare to HCA and THC?
Jiangxi Rimag Group Co's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Jiangxi Rimag Group Co and its competitors. Jiangxi Rimag Group Co's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Rimag Group Co stock overvalued right now?
Jiangxi Rimag Group Co (FRA:RD9) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Jiangxi Rimag Group Co's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Jiangxi Rimag Group Co (FRA:RD9), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Rimag Group Co Ltd is a medical group specializing in medical imaging in China. The company generates revenue through these segments: Imaging Center Services, Imaging Solution Services, and Digital-intelligence services. The Imaging Center Services include examination and diagnostic services to patients and other healthcare consumers via its flagship imaging centers, such as MRI, CT, PET, X-ray, ultrasound and mammography. Majority of the revenue comes from Imaging center services. Geographically, the company operates in Chinese Mainland and Overseas (including Hong Kong and Macau). It generates maximum revenue from Chinese Mainland.
14GF Score
Get the complete analysis for FRA:RD9
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RD9 has been successfully added to your 
